Opexa Therapeutics, Inc. is a biopharmaceutical company that develops personalized cellular therapies to treat multiple sclerosis (MS) using its proprietary T-cell technology. Its leading therapy candidate includes Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. For more information, visit the company’s website at www.opexatherapeutics.com.